-transparent.png){kind=logo}
We present three patients in whom Fluosol-DA 20 percent was administered in the presence of ischemic cerebral vascular disease. While transient improvement observed in two cases may have been related to Fluosol-DA administration it is premature to use these results to comment on the potential protective or therapeutic efficacy of Fluosol-DA in ischemic cerebral vascular disease. One patient progressively deteriorated neurologically during and after the infusion. Our initial impressions are limited to the observations that Fluosol-DA in doses of 20 ml/kg can be administered easily and without major effects on hemodynamic or pulmonary function. One patient had a transient leukopenia.
K W Swann, and
A H Ropper, and
N T Zervas
January 1982,
Neurological research,
K W Swann, and
A H Ropper, and
N T Zervas
January 1981,
Stroke,
K W Swann, and
A H Ropper, and
N T Zervas
June 1982,
No shinkei geka. Neurological surgery,
K W Swann, and
A H Ropper, and
N T Zervas
January 1992,
Biomaterials, artificial cells, and immobilization biotechnology : official journal of the International Society for Artificial Cells and Immobilization Biotechnology,
K W Swann, and
A H Ropper, and
N T Zervas
August 1982,
Neurologia medico-chirurgica,
K W Swann, and
A H Ropper, and
N T Zervas
December 1981,
No shinkei geka. Neurological surgery,
K W Swann, and
A H Ropper, and
N T Zervas
December 1981,
Neurologia medico-chirurgica,
K W Swann, and
A H Ropper, and
N T Zervas
January 1985,
International anesthesiology clinics,
K W Swann, and
A H Ropper, and
N T Zervas
May 1984,
Critical care medicine,
